Excitatory amino acid receptors and disease.
Recent advances in the molecular biology of excitatory amino acid receptors are reviewed. Evidence that drugs blocking the excitatory action of glutamate at the N-methyl-D-aspartate (NMDA) and non-NMDA receptors may be of clinical use in epilepsy, Parkinson's disease, cerebral ischaemia and trauma, acquired immune deficiency syndrome (AIDS) encephalopathy and neuropathic pain is summarized.
Meldrum
B S
BS
Department of Neurology, Institute of Psychiatry, De Crespigny Park, Denmark Hill, London, UK.
D000596:Amino Acids / Q000502:physiology*; D006801:Humans; D009420:Nervous System / Q000503:physiopathology; D009422:Nervous System Diseases / Q000503:physiopathology*; D018091:Receptors, AMPA; D017459:Receptors, Amino Acid; D011956:Receptors, Cell Surface / Q000502:physiology*; D017470:Receptors, Glutamate; D018092:Kainic Acid Receptors; D016194:Receptors, N-Methyl-D-Aspartate / Q000502:physiology; D017981:Receptors, Neurotransmitter / Q000502:physiology
D000596:Amino Acids; D018091:Receptors, AMPA; D017459:Receptors, Amino Acid; D011956:Receptors, Cell Surface; D017470:Receptors, Glutamate; D018092:Kainic Acid Receptors; D016194:Receptors, N-Methyl-D-Aspartate; D017981:Receptors, Neurotransmitter